HIRU and HTDS announce finalization of MindUp BioResearch Division sale

This is a joint press release of Hiru Corporation (HIRU) and Hard to Treat Diseases (HTDS) - The two companies are pleased to announce the finalization and completion of the purchase and sale of the MindUp BioResearch Division. Details of the transaction completed on cash and stock basis can be found at the Pink Sheets web site www.pinksheets.com under the "filings" tab.

The buyer Hiru focuses on production and manufacturing of premium herbs, herbal extracts and herbal preparations. The company markets its herbal curatives across the Chinese market. The company's modern production and distribution methods hoisted the company's nation-wide reputation. The company became the leading private enterprise in agricultural industrialization in Chinese Jiangxi Province and earned the China national Good Manufacturing Practice & Implementation certificates.

In other news and events of Hiru, the company continues to seek other merger candidates. The company is seeking to reach the $100 million dollar revenue mark in the next 24 to 36 months. Hiru, a well developed China based company with a solid client base, currently enjoys gross revenues of (for the 11 months ended November 30, 2009) $27.3 million with a net profit of $4.795 million.

HTDS is a holdco of a China based Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Mellow Hope is the biggest exporter of Biological Vaccines in China. Other controlling interests include an East European (Serbian) medical company, Slavica Biochem whose experts are performing cutting edge research in the field of neurological impairments in Multiple Sclerosis (MS) and Traumatic Brain Injury (TBI).

In other news and events of HTDS, the company has completed its preliminary Q4 results. The financial numbers and comparisons will shortly be released by the company. The company is pleased with the preliminary financial results. As previously announced contracts, and revenues commence they are beginning to show up on the company books. The company has already started with its 1st phase of the stem cell bank development and intends to post its plan of action as filings with Pink Sheets shortly. The plan will include new laboratory, offices, equipment and the launch date.

Details of Hiru business activities can be found at this web site http://www.hirucorporation.com and Hard To treat Diseases at http://www.htdsmedical.com